Alder BioPharmaceuticals (NASDAQ: [[ticker:ALDR]]) has named Erin LaVelle to the newly created position of chief operating officer. Before joining Bothell, WA-based Alder, Lavelle was the general manager of the Taiwanese affiliate of Amgen (NASDAQ: [[ticker:AMGN]]). Alder says Lavelle will lead strategy and planning as the company prepares to bring its migraine drug, eptinezumab, to the market. The company has said it expects to file for FDA approval of the migraine drug later this year.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
